JPH0539218A - Therapeutic agent for radiation injury - Google Patents
Therapeutic agent for radiation injuryInfo
- Publication number
- JPH0539218A JPH0539218A JP3195342A JP19534291A JPH0539218A JP H0539218 A JPH0539218 A JP H0539218A JP 3195342 A JP3195342 A JP 3195342A JP 19534291 A JP19534291 A JP 19534291A JP H0539218 A JPH0539218 A JP H0539218A
- Authority
- JP
- Japan
- Prior art keywords
- injuries
- therapeutic agent
- melting point
- acid polymer
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 6
- 208000019155 Radiation injury Diseases 0.000 title abstract description 4
- 230000006378 damage Effects 0.000 claims abstract description 10
- 230000003394 haemopoietic effect Effects 0.000 claims abstract description 6
- 238000002844 melting Methods 0.000 claims abstract description 5
- 230000008018 melting Effects 0.000 claims abstract description 5
- 238000004220 aggregation Methods 0.000 claims abstract description 3
- 230000002776 aggregation Effects 0.000 claims abstract description 3
- 230000001681 protective effect Effects 0.000 claims abstract description 3
- 239000013078 crystal Substances 0.000 claims abstract 2
- 230000005855 radiation Effects 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 3
- 150000002291 germanium compounds Chemical class 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 11
- 229920000642 polymer Polymers 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 239000002775 capsule Substances 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 239000002552 dosage form Substances 0.000 abstract description 4
- 239000000843 powder Substances 0.000 abstract description 4
- 238000001959 radiotherapy Methods 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 4
- 208000027418 Wounds and injury Diseases 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 3
- 239000008187 granular material Substances 0.000 abstract description 3
- 230000005484 gravity Effects 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- 208000032484 Accidental exposure to product Diseases 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 231100000818 accidental exposure Toxicity 0.000 abstract description 2
- 239000006187 pill Substances 0.000 abstract description 2
- 239000000829 suppository Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- -1 organogermanium compound Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 231100000569 acute exposure Toxicity 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920003114 HPC-L Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は 式 ［（Ｏ1/2 ）３Ｇ
ｅＣＨ２ＣＨ２ＣＯＯＨ］ｎ （式中ｎは１又はそれ以上の整数を意味する）にて示さ
る３−オキシゲルミルプロピオン酸からなる放射線障害
治療剤に係る。The present invention relates to the formula [(O 1/2 ) 3 G
eCH 2 CH 2 COOH] n (wherein n represents an integer of 1 or more) according to the radiation injury therapeutic agent comprising Shimesaru 3 oxygermylpropionic acid at.
【０００２】[0002]
【従来技術】放射線医療、原発、放射性物質保管施設等
の取扱従業者や事故発生時の近郊住民の被爆は最近地球
的環境破壊問題として注目されている。また放射線医療
特に悪性腫瘍に対する放射線療法は照射に伴う急性障害
の発生が有効な治療の妨げとなっている。2. Description of the Related Art Radiation medical treatment, nuclear power plants, radioactive materials storage facilities, and the like, and the exposure of workers in the suburbs at the time of an accident have received attention as a global environmental destruction problem. Radiation therapy, especially for radiation therapy for malignant tumors, is hindering effective treatment due to the occurrence of acute damage associated with irradiation.
【０００３】被爆100 〜500 rem では造血臓器の障害
が、500 〜2000rem では消化管症状が、それ以上の被爆
では中枢神経系の症状が支配的とされ、ＬＤ
１００／３０日は約700 rem、ＬＤ５０／３０日は約400
remである。At 100 to 500 rem, hematopoietic organ disorders are predominant, at 500 to 2000 rem, gastrointestinal symptoms are predominant, and at more than 100 rem, central nervous system symptoms are predominant.
100/30 days is about 700 rem, LD 50/30 days is about 400
rem.
【０００４】急性被爆では25rem程度でも造血機能障害
が発生し増悪期より回復期を経ずに短時間の間に死亡す
る例も報告されており、急性被爆に対する延命効果の高
い薬剤の出現が望まれていた。[0004] In acute exposure, it has been reported that hematopoietic dysfunction occurs even at about 25 rem and death occurs within a short period of time from the exacerbation period to the recovery period, and the emergence of a drug with a long life-prolonging effect on acute exposure is desired. It was rare.
【０００５】また、３−オキシゲルミルプロピオン酸は
複雑な重合性を有し、多用な用途を有するため薬理活性
の面から近年極めて注目されている化合物であり、抗ウ
イルス作用など古くから注目されていたが、被爆障害の
治療効果については知られていない。（特公昭57-53800
号等）Further, 3-oxygermylpropionic acid is a compound which has received a great deal of attention in recent years from the viewpoint of pharmacological activity because it has complex polymerizability and has various uses. However, it is not known about the therapeutic effect on A-bomb injury. (Japanese Patent Publication Sho 57-53800
No.)
【０００６】被爆が予測される場合はラジカル消去剤が
一般的に利用されているが、偶発的に放射性物質を摂取
したり、被爆してしまったような場合は排泄促進剤やア
デニン、レシチン、パロチン等の代謝性薬剤いわゆる栄
養剤的なものしかなく、決定的な治療方法がないのが現
状である。Radical scavengers are generally used when exposure is predicted, but in the case of accidental intake of radioactive substances or exposure, excretion enhancers, adenine, lecithin, The current situation is that there is no definitive treatment method because there are only metabolic drugs such as parotin, which are so-called nutritional drugs.
【０００７】本発明者は上記の実情に鑑み、被爆障害を
有効に軽減、回復する事の出来る物質を得るために検索
し、本発明を完成するに至った。すなわち本発明は偶発
的被爆や癌の放射線療法等にあって、高頻度で発生する
造血機能障害に対する救命効果の高い薬剤を提供するも
のである。In view of the above situation, the present inventor has completed the present invention by searching for a substance capable of effectively reducing and recovering radiation damage. That is, the present invention provides a drug having a high life-saving effect against frequently occurring hematopoietic dysfunction in accidental exposure, radiation therapy for cancer, and the like.
【０００８】[0008]
【問題点を解決するための手段及び作用】本発明は安全
性の高い、比重（密度）２．２３、溶解度（水）１．５
７（２０°Ｃ）、融点約２３０°Ｃ（付近凝集）の物理
化学的性質を有する３−オキシゲルミルプロピオン酸重
合体を放射線被爆障害の治療剤として利用するものであ
る。[Means and Actions for Solving Problems] The present invention is highly safe and has a specific gravity (density) of 2.23 and a solubility (water) of 1.5.
A 3-oxygermylpropionic acid polymer having a physicochemical property of 7 (20 ° C) and a melting point of about 230 ° C (aggregation in the vicinity) is used as a therapeutic agent for radiation exposure damage.
【０００９】なお、製剤加工にあっては３−オキシゲル
ミルプロピオン酸重合体の活性を維持するため圧縮製剤
の場合は水溶解性の高い低分子性物質ことに白糖、ソル
ビトール、果糖、ショ糖、ブドウ糖、乳糖、マンニトー
ルによる組成物が、顆粒剤、カプセル剤、散剤の場合は
ヒドロキシプロピルセルロース（ＨＰＣ）、アルブミ
ン、ペプシン等の高分子性物質によって安定化された組
成物形態の利用が好ましい。In order to maintain the activity of the 3-oxygermylpropionic acid polymer during processing of the preparation, in the case of the compressed preparation, a low molecular weight substance having high water solubility, particularly sucrose, sorbitol, fructose and sucrose. In the case of granules, capsules, and powders, the composition of glucose, lactose, and mannitol is preferably used in the form of a composition stabilized by a polymeric substance such as hydroxypropyl cellulose (HPC), albumin, and pepsin.
【００１０】[0010]
【剤型及び投与量】本発明による固形製剤の剤型として
は、通常は経口用に圧縮加工された錠剤、カプセル剤、
散剤、顆粒剤の形態で使用されるが、トロ−チ剤、丸
剤、坐剤等としても使用可能である。[Dosage Form and Dosage] The dosage form of the solid preparation according to the present invention is usually orally compressed tablets, capsules,
It is used in the form of powder or granules, but can also be used as troches, pills, suppositories and the like.
【００１１】なお、３−オキシゲルミルプロピオン酸重
合体を人に投与する場合の投与量としては、剤型、患者
の年齢等に依存するが、一般には１〜１５００mg/kg 範
囲内であり、成人（体重５０kg）に対する経口投与では
１５０mg／日程度が好ましい。The dose of the 3-oxygermylpropionic acid polymer administered to a human depends on the dosage form, the age of the patient, etc., but is generally in the range of 1 to 1500 mg / kg. Oral administration to an adult (body weight 50 kg) is preferably about 150 mg / day.
【００１２】以下には本発明の効果を、実施例により更
に詳細に説明する。The effects of the present invention will be described in more detail below with reference to examples.
【００１３】[0013]
【００１４】製剤例１（散 剤） ヒドロキシプロピルセルロース、３−オキシゲルミルプ
ロピオン酸重合体２：１をエタノールを湿潤剤として練
合し、50゜Ｃ以下の温度で乾燥後粉末又は粒状の組成物
を得た。Formulation Example 1 (Powder) Hydroxypropyl cellulose and 3-oxygermylpropionic acid polymer 2: 1 were kneaded with ethanol as a wetting agent, dried at a temperature of 50 ° C. or lower, and then powdered or granular composition. I got a thing.
【００１５】製剤例２（カプセル剤） 以下処方でカプセル剤を調整した。 本発明による３−オキシゲルミルプロピオン酸重合体 10mg 乳 糖 165.5mg ＨＰＣ（ヒドロキシプロピルセルロース） 2.7mg ステアリン酸マグネシウム 1.8mg １カプセルあたり 180mg Formulation Example 2 (Capsule) A capsule was prepared according to the following formulation. 3-Oxygermylpropionic acid polymer according to the present invention 10 mg Lactose 165.5 mg HPC (hydroxypropyl cellulose) 2.7 mg Magnesium stearate 1.8 mg 180 mg per capsule
【００１６】製剤例３（錠 剤） 以下処方で圧縮錠剤を調整した。 ３−オキシゲルミルプロピオン酸重合体 10.0 ソルビトール 41.7 果 糖 1.2 ＨＰＣーＬ 3.0 ステアリン酸マグネシウム 1.8 白 糖 適 量 180.0mg Formulation Example 3 (tablets) Compressed tablets were prepared according to the following formulation. 3-Oxygermylpropionic acid polymer 10.0 Sorbitol 41.7 Fructose 1.2 HPC-L 3.0 Magnesium stearate 1.8 White sugar Suitable amount 180.0 mg
【００１７】薬効薬理試験例 １）放射線障害防護作用 （ａ）被験薬物 製造例３の薬剤Pharmacological and Pharmacological Test Example 1) Radiation Damage Protective Action (a) Test Drug Drug of Production Example 3
【００１８】（ｂ）試験方法 試験動物としてはｄｄＹ系雄性マウス（５週齢）を一群
１０匹で使用した。なお、すべてのマウスは腸内細菌の
感染を抑制するために抗生物質を投与した。軟Ｘ線照射
装置にて等電圧１４０ｋｖ、照射量６５０レントゲン
（Ｒ）をマウスに照射して３０日後の生存率および平均
生存日数を調べた。(B) Test method As test animals, male ddY mice (5 weeks old) were used in groups of 10. All mice were administered with antibiotics in order to suppress the infection of intestinal bacteria. Mice were irradiated with an equal voltage of 140 kv and an irradiation dose of 650 roentgen (R) using a soft X-ray irradiation device, and the survival rate and the average survival time after 30 days were examined.
【００１９】被験薬物は０．５％ゼラチン溶液に溶解し
て照射直後に単回経口投与、または照射直後から３日間
３回連続経口投与を行った。The test drug was dissolved in a 0.5% gelatin solution and orally administered once immediately after irradiation, or continuously 3 times for 3 days immediately after irradiation.
【００２０】（ｃ）結果 結果は以下の表 １に記載のごとく、本発明組成物は非
投与群に比べて生存率および平均生存日数を有意に延長
し明らかな放射線障害防護並びに救命作用を示した。(C) Results As shown in Table 1 below, the composition of the present invention significantly prolongs the survival rate and the average survival time as compared with the non-administered group, and shows a clear radiation damage protection and life-saving effect. It was
【００２１】[0021]
【表 １】 生存率および平均生存日数 群設定 生存率（％） 平均生存日数（日） 非投与 １０ １２．０ 1 mg/Kg 単回 ２０ １５．３ 10 mg/Kg 単回 ４０ １９．８ ＊ 100 mg/Kg 単回 ５０ ２０．８ ＊ 1 mg/Kg ３回 ３０ １９．１ ＊ 10 mg/Kg ３回 ４０ １９．９ ＊ 100 mg/Kg ３回 ５０ ２１．６ ＊ ＊：有意水準ｐ＜０．０５で非投与群と有意差あり[Table 1] Survival rate and average survival days Group setting Survival rate (%) Average survival time (days) Non-administration 10 12.0 1 mg / Kg Single dose 20 15.3 10 mg / Kg Single dose 40 19.8 * 100 mg / Kg Single 50 20.8 * 1 mg / Kg 3 times 30 19.1 * 10 mg / Kg 3 times 40 19.9 * 100 mg / Kg 3 times 50 21.6 * *: Significance level p < 0.05 is significantly different from non-administered group
【００２２】[0022]
【発明の効果】本発明は３−オキシゲルミルプロピオン
酸の放射線障害防護並びに救命作用の発見によるもので
あり被爆に対して増悪期より回復期を経ずに死に至る重
篤症例に対しても救命効果の高い薬剤を提供するもので
ある。INDUSTRIAL APPLICABILITY The present invention is based on the discovery of protection against radiation damage and life-saving action of 3-oxygermylpropionic acid, and even in serious cases of exposure to death without a recovery period from an exacerbation period to a death. It provides a drug with a high life-saving effect.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 三 谷 隆 彦 名古屋市東区東外堀町35番地 株式会社三 和化学研究所内 (72)発明者 横 地 祥 司 名古屋市東区東外堀町35番地 株式会社三 和化学研究所内 ─────────────────────────────────────────────────── ─── Continuation of front page (72) Inventor Takahiko Mitani 35 Higashi Sotobori-cho, Higashi-ku, Nagoya City Sanwa Chemical Research Institute Co., Ltd. Sanwa Institute of Chemistry
Claims (2)
ＯＨ］ｎ （式中ｎは１又はそれ以上の整数を意味する）にて示さ
れ、白色針状結晶を有し融点が２３０°Ｃ（付近凝集）
である有機ゲルマニウム化合物を有効成分として含有す
る放射線障害治療剤1. The formula [(O 1/2 ) 3 GeCH 2 CH 2 CO
OH] n (wherein n represents an integer of 1 or more) and has white needle crystals and a melting point of 230 ° C. (aggregation in the vicinity).
Radiation Damage Remedy Containing an Organic Germanium Compound of
有する請求項１記載の放射線障害治療剤2. The therapeutic agent for radiological disorders according to claim 1, which has a protective effect on hematopoietic dysfunction due to radiation irradiation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3195342A JPH0539218A (en) | 1991-08-05 | 1991-08-05 | Therapeutic agent for radiation injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3195342A JPH0539218A (en) | 1991-08-05 | 1991-08-05 | Therapeutic agent for radiation injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0539218A true JPH0539218A (en) | 1993-02-19 |
Family
ID=16339577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3195342A Pending JPH0539218A (en) | 1991-08-05 | 1991-08-05 | Therapeutic agent for radiation injury |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0539218A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014017046A1 (en) | 2012-07-23 | 2014-01-30 | 国立大学法人東京大学 | Prophylactic and/or therapeutic agent for radiation damage |
| US11782344B2 (en) | 2015-04-21 | 2023-10-10 | Fujifilm Electronic Materials U.S.A., Inc. | Photosensitive polyimide compositions |
-
1991
- 1991-08-05 JP JP3195342A patent/JPH0539218A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014017046A1 (en) | 2012-07-23 | 2014-01-30 | 国立大学法人東京大学 | Prophylactic and/or therapeutic agent for radiation damage |
| US9895331B2 (en) | 2012-07-23 | 2018-02-20 | The University Of Tokyo | Prophylactic and/or therapeutic agent for radiation damage |
| US11782344B2 (en) | 2015-04-21 | 2023-10-10 | Fujifilm Electronic Materials U.S.A., Inc. | Photosensitive polyimide compositions |
| US11899364B2 (en) | 2015-04-21 | 2024-02-13 | Fujifilm Electronic Materials U.S.A., Inc. | Photosensitive polyimide compositions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0500823B1 (en) | Antimalarial compositions | |
| US4757072A (en) | Carcinostatic agent | |
| RU2170578C2 (en) | Pharmaceutical composition containing n-chlorophenylcarbamates or n- chlorophenylthiocarbamates and derivatives of n-phospho-noglycine for inhibition of malignant neoplasms growth and viruses in mammals | |
| WO1991002529A2 (en) | Product and method for killing abnormal vertebrate cells | |
| HU198388B (en) | Process for producing pharmaceutical compositions containing amides of carboxylic acids for treating rheumatic and inflammatoric illnesses | |
| Barbhaiya et al. | Clinical pharmacological studies of amoxycillin: effect of probenecid. | |
| JPH0539218A (en) | Therapeutic agent for radiation injury | |
| EP0600582B1 (en) | Treatment for muscular dystrophy | |
| US3852453A (en) | Method of enhancing vincamine compositions | |
| JPH0269417A (en) | Schizophrenia treatment composition | |
| WO1991017751A1 (en) | Orally administrable gallium compositions and methods of treatment therewith | |
| WO2001049269A1 (en) | Sustained-releasing anthelmintic compositions comprising praziquantel | |
| JPH059116A (en) | 3-oxygermylpropionic acid composition and cytopathic inhibitor consisting essentially of the same composition | |
| US3256149A (en) | Compositions comprising an alkaloid of mitragyna speciosa and methods of using same | |
| JPH01221316A (en) | Cerebral circulatory metabolism-improving agent | |
| JPH06145057A (en) | Agent for protecting radiation damage | |
| US3257277A (en) | Synergistic antihypertensive compositions | |
| JP2004315470A (en) | Pharmaceutical preparation containing sodium iodide | |
| JPH01135718A (en) | Radiation damage treatment drug | |
| JPH03502802A (en) | Antiemetic ergoline derivative | |
| RU2745985C1 (en) | Anticoronavirus therapeutic agent - substituted 7-hydroxy-3,4,12,12a-tetrahydro-1h-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione for the prevention and treatment of covid-19 | |
| JPH0333715B2 (en) | ||
| JP2010265209A (en) | Iodine liquid preparation | |
| JPS63190827A (en) | Treating and preventive agent for ulcer and gastritis | |
| US2991225A (en) | Omicron-methylbenzhydryl-beta-dimethylaminoethyl ether process and composition for symptomatic relief of the syndrome of parkinsonism and of spastic skeletal muscle disorders |